The Abu Dhabi Stem Cells Centre (ADSCC) has successfully treated six cancer patients since introducing the Abu Dhabi Bone Marrow Transplant programme (AD-BMT) in July 2020.
The duration of treatment for patients, with different types of blood malignancies like Multiple Myeloma, Plasma Cell Leukemia, Large Diffuse B-Cell Lymphoma and Hodgkin Lymphoma, ranged between 19 days and up to a month.
The AD-BMT programme was established to provide the highest standard of care in the field of Hematopoietic Stem Cells Transplant.
Its exemplary clinical results have enabled ADSCC to seek international accreditation and to set the template to facilitate its expansion to offer other procedures and treatments.
The programme will soon expand capacity to be able to treat more than one patient simultaneously.
It will also look at treating not only patients with hematological conditions, but also patients with autoimmune diseases and primary immune deficiencies.


UAE air defences intercept 5 missiles, 17 drones on Tuesday
UAE hosts Eid Al Fitr carnival for children in Gaza
UAE carries out over 8,000 inspections across markets to protect consumers
UAE condemns Iranian attacks on Bahrain
UAE President and NATO Secretary General discuss regional developments
UAE, Slovenia condemn Iran attacks and regional developments
UAE hosts the operation to release an American citizen from Afghanistan
Sheikh Abdullah expresses solidarity with Turkey over helicopter crash
